A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients with Solid Tumors and in Combination with Temozolomide in Patients with Advanced and/or Metastatic Melanoma

Trial Profile

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients with Solid Tumors and in Combination with Temozolomide in Patients with Advanced and/or Metastatic Melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2015

At a glance

  • Drugs Lenvatinib (Primary) ; Temozolomide
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Eisai Inc
  • Most Recent Events

    • 02 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jan 2015 Planned primary completion date changed from 1 Nov 2011 to 1 Sep 2011, as reported by ClinicalTrials.gov.
    • 27 Jan 2015 Status changed from completed to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top